

Company Announcement

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, February 20, 2020 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today received information about the following transactions of the company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.

1.	Details of the person discharging managerial responsibilities/person closely associated				
a)	Name	Henrik Juuel			
2.	Reason for the notification				
a)	Position/status	Executive Vice President and Chief Financial Officer of Bavarian Nordic A/S			
b)	Initial notification/Amendment	Initial notification			
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor				
a)	Name	Bavarian Nordic A/S			
b)	LEI	2138006JCDVYIN6INP51			
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted				
a)	Description of the financial instrument, type of instrument	Restricted Stock Units			
	Identification code	DK0015998017			
b)	Nature of the transaction	Grant			
c)	Price(s) and volume(s)	Price(s)	Volume(s)		
		DKK 159.9	4,625		
d)	Aggregated information - Aggregated volume - Price	4,625 DKK 739,694.00			
e)	Date of the transaction	2020-02-20			
f)	Place of the transaction	Outside a trading venue			

1.	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name	Henrik Birk	
2.	Reason for the notification		
a)	Position/status	Executive Vice President and Chief Operating Officer of Bavarian Nordic A/S	
b)	Initial notification/Amendment	Initial notification	
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Bavarian Nordic A/S	
b)	LEI	2138006JCDVYIN6INP51	

4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
a)	Description of the financial instrument, type of instrument	Restricted Stock Units		
	Identification code	DK0015998017		
b)	Nature of the transaction	Grant		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		DKK 159.9	4,224	
d)	Aggregated information - Aggregated volume - Price	4,224 DKK 675,516.00		
e)	Date of the transaction	2020-02-20		
f)	Place of the transaction	Outside a trading venue		

1.	Details of the person discharging managerial responsibilities/person closely associated				
a)	Name	Tommi Kainu			
2.	Reason for the notification				
a)	Position/status	Executive Vice President and Chief Business Officer of Bavarian Nordic A/S			
b)	Initial notification/Amendment	Initial notification			
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor				
a)	Name	Bavarian Nordic A/S			
b)	LEI	2138006JCDVYIN6INP51			
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted				
a)	Description of the financial instrument, type of instrument	Restricted Stock Units DK0015998017			
	Identification code				
b)	Nature of the transaction	Grant			
c)	Price(s) and volume(s)	Price(s)	Volume(s)		
		DKK 159.9	4,209		
d)	Aggregated information - Aggregated volume - Price	4,209 DKK 673,200.00			
e)	Date of the transaction	2020-02-20			
f)	Place of the transaction	Outside a trading venue			

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and has been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an investigational Ebola vaccine, licensed to Janssen. For more information visit www.bavarian-nordic.com.

Contacts

Rolf Sass Sørensen Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Graham Morrell Paddock Circle Advisors (US) graham@paddockcircle.com

Tel: +1 781 686 9600

Company Announcement no. 7 / 2020